Inozyme Pharma Inc ENPP1 Deficiency Program Update Call Transcript
Good morning and thank you for joining us for ENPP1 Deficiency Program update call. Before we begin our formal remarks, I would like to point you to our forward-looking statements disclaimer. I would like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties. These risks and uncertainties are outlined in the company's recent filings with the Securities and Exchange Commission, which we urge you to read.
We undertake no obligation to update or revise any forward-looking statements to reflect new information or future events, except as required by law. Our actual results may differ materially from what is discussed on today's call. I would now like to turn the conference over to Douglas Treco, Chief Executive Officer, and Chairman of the Board of Directors of Inozyme Pharma. Please go ahead.
Thank you, Stefan. At Inozyme, we're developing transformative therapies for rare
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
